S-Adenosylmethionine decarboxylase is a key enzyme for the synthesis of polyamines in mammals, plants and many other species that use aminopropyltransferases for this pathway. It catalyses the formation o f S -a d e n o s y l -1 -( m e t h y l t h i o ) -3 -p r o p y l a m i n e ( d e c a r b o x y l a t e d S-adenosylmethionine), which is used as the aminopropyl donor. This is the sole function of decarboxylated S-adenosylmethionine. Its content is therefore kept very low and is regulated by variation in the activity of S-adenosylmethionine decarboxylase according to the need for polyamine synthesis. All S-adenosylmethionine decarboxylases have a covalently bound pyruvate prosthetic group, which is essential for the decarboxylation reaction, and have similar structures, although they differ with respect to activation by cations, primary sequence and subunit composition. The present chapter describes these features, the mechanisms for autocatalytic generation of the pyruvate from a proenzyme precursor and for the decarboxylation reaction, and the available inhibitors of this enzyme, which have uses as anticancer and anti-trypanosomal agents. The intricate mechanisms for regulation of mammalian S-adenosylmethionine decarboxylase activity and content are also described.
Introduction
Polyamines are small basic molecules found in virtually all living cells. Although diamines are frequently referred to as polyamines, they are really precursors and polyamines are molecules with more than two positively charged nitrogen atoms. Two general pathways for synthesis of such polyamines have been described. By far the best known and most studied route requires the addition of aminopropyl groups catalysed by aminopropyltransferases that use dcAdoMet [decarboxylated AdoMet (S-adenosylmethionine); S-adenosyl-1-(methylthio) -3-propylamine] (Figure 1 ) as a substrate. This is the pathway used by many bacteria, archaea, fungi and higher organisms including mammals and plants [1, 2] , and was fi rst characterized by Herbert and Celia Tabor using Escherichia coli [3] . The second pathway, which was described by Tait in 1976 [4] , employs aspartate β-semialdehyde as the aminopropyl group donor in a fusion reaction to form carboxyspermidine or carboxynorspermidine, which is then decarboxylated. This pathway is present in Vibrio cholerae and many other bacteria [5] .
The present chapter will describe in detail the properties and regulation of AdoMetDC (AdoMet decarboxylase), which is essential for the fi rst pathway. The presence of a gene encoding AdoMetDC is therefore a diagnostic feature of organisms that use the aminopropyl transfer pathway. Supply of dcAdoMet limits the conversion of putrescine into the higher polyamines in such species and AdoMetDC is the key regulatory step in the biosynthetic pathway. Once converted into dcAdoMet, AdoMet is exclusively utilized for polyamine biosynthesis; there are no other known reactions that use dcAdoMet as a substrate, except for an acetylation reaction described below.
Figure 1. The AdoMetDC reaction and the synthesis of polyamines by aminopropyltransferases
The aminopropyl group is shown in blue. The aminopropyltransferase reaction shown is with putrescine (R=H) or spermidine R=N + H 3 (CH 2 ) 3 as a substrate. Known aminopropyltransferases can add aminopropyl groups to other substrates such as agmatine, 1,3-diaminopropane, 1,5-diaminopentane and a variety of polyamines made up of aminobutyl or aminopropyl units [2, 9] .
Strucure and function of AdoMetDC
Nature of the AdoMetDC reaction and activation by effectors of low molecular mass or binding of other proteins All AdoMetDCs are synthesized as a proenzyme (π chain) and are made up of α and β subunits that are formed from it. The fi rst AdoMetDC to be characterized was from E. coli [3] . This enzyme requires Mg 2+ [12] . The second AdoMetDC was from mammals; it was found to be unaffected by Mg 2+ , but required putrescine for maximal activity [13] . Subsequent work has found that putrescine-activated AdoMetDCs are widespread and present in fungi, protozoa and nematodes; however, AdoMetDCs in plants have no known effectors and are not activated by putrescine or by Mg 2+ [14, 15] . Quite recently, it has been found that AdoMetDCs in trypanosomes form a heterodimer with a catalytically inactive paralogue of the π chain called proenzyme (π′). This greatly stimulates the activity [16] .
AdoMetDCs can be divided into fi ve classes based on sequence at the cleavage site, structural considerations and their activation by cations (Table 1) . Class I enzymes include those from bacterial and archaeal sources. All have αβ subunit structures, but may be monomers, dimers or tetramers of these units. They can be divided into Mg 2+ -activated Class IA representing Gram-negative bacteria, and Class IB from Gram-positive bacteria and archaeabacteria, which have no requirement for Mg 2+ . Class II enzymes include those from mammals, plants, fungi and trypanosomes. Those in Class IIA, such as AdoMetDCs from mammals, are (αβ) 2 dimers and are putrescine-activated. Class IIB enzymes, such as those from plants, are αβ monomers and are not activated by putrescine. Class IIC contains the heterodimeric enzymes from trypanosomes, which have the subunit structure αβπ′. The AdoMetDC from Plasmodium falciparum is a bifunctional protein with a C-terminal domain that encodes ODC [17] .
Structural studies of AdoMetDCs
Crystal structures are now available for AdoMetDC proteins from three species: human, potato and Thermotoga maritima. Structures of the unprocessed proenzyme π chain [18] and the processed human enzyme in the presence of inhibitors and substrate analogues, as well as in the absence and presence of the putrescine activator, have been obtained [18] [19] [20] [21] . Also, there are structures for the processed potato AdoMetDC [15] and the π proenzyme from T. maritima [22] . A model of the P. falciparum structure has been published [17] .
Human AdoMetDC is an (αβ) 2 dimer from Class IIA (Figures 2A  and 2B ). Each αβ monomer is a novel four-layer α/β-sandwich fold, in which two central eight-stranded antiparallel β-sheets are fl anked by several α-helices on each outer side. The β subunit contributes three β-strands, one α-helix and one short 3 10 -helix. The α subunit contributes 13 β-strands, fi ve α-helices and three short 3 10 -helices. The six α-helices observed in the monomer are all amphipathic, packing tightly against the outer faces of the β sandwich. The region between the α-helices and the β-sheets is very hydrophobic. The overall structure of the potato enzyme is similar to human AdoMetDC, but the potato enzyme is an αβ monomer [15] . Residues at the dimer interface of human AdoMetDC are replaced in the potato structure and these substitutions create steric confl icts preventing dimerization.
There is very little overall primary sequence similarity between the Class I and the Class II AdoMetDCs. However, the crystal structure of the T. maritima AdoMetDC Class IB π proenzyme shows that the overall structure is remarkably similar to the Class II eukaryotic AdoMetDC αβ (Figures 2A and 2B) , suggesting an evolutionary link between them [22] . The main differences between the human and T. maritima structures are a result of several insertions in the human protein, which occur primarily relative to the Figure 2B ). The insertions form two additional β-strands in both the N-and C-terminal halves of the protein, an additional α-helix in the N-terminal half, as well as a loop region that connects the N-and C-terminal halves of the human structure. Two of the additional β-strands are involved in the (αβ) 2 dimer interface of the human AdoMetDC. The dimer interface of the T. maritima AdoMetDC contains the active site, which is made up of residues from The upper part of (A) shows the human (αβ) 2 dimer of processed human AdoMetDC, which has one active site in each unit, and the structure of the T. maritima π chain which could give rise to an (αβ) 2 dimer with two active sites at the positions shown (see [22] ). The lower part of (A) shows the dimer (native active form) and monomer of human spermine synthase [9] , and the similarity of its N-terminal domain to AdoMetDC. (B) shows a comparative topology diagram of the arrangement of α helices (circles) and β sheets (triangles) of the human π and T. maritima π 2 chains. The unfi lled segments (α3, β7, β8, β15 and β16) of the human protein are not present in the T. maritima structure. Note that the T. maritima structure is of the π 2 dimer and has two potential cleavage sites for pyruvate formation. The human sequence diverges in one of the two sites and forms only one pyruvate prosthetic group. (C) shows a sequence comparison between (i) portions of the human and T. maritima AdoMetDCs and (ii) portions of the E. coli and T. maritima AdoMetDCs. The alignment in (i) is based on the superimposition of the crystal structures and the α-helices and β-strands are marked. The alignment in (ii) is based on the sequence similarity between the E. coli and T. maritima AdoMetDCs, which can be used to generate a model of the E. coli structure for which experimental data is not available [22] . both αβ units. There are likely to be two active sites in the (αβ) 2 dimer (Figures 2A and 2B) [22] . However, the only structure available is of the unprocessed π 2 chain and it is not certain that both sites do process, since processing of one site could infl uence that of the other. In light of recent data on the active form of the Trypanosoma AdoMetDCs being αβπ . [16] , this question requires further study. A number of key residues involved in protein processing, substrate binding and catalysis are positioned in the structure in similar places and can readily be identifi ed, not only in the T. maritima structure, but also in the Class IA E. coli sequence for which no structure is currently available ( Figure 2C ). Remarkably, the recent determination of the structure of human spermine synthase shows that it has an N-terminal domain with a structure that is extremely similar to AdoMetDC, although there is little identity at the amino acid sequence level [9] . Spermine synthase is a homodimer and each monomer consists of a C-terminal domain, which contains the active site, a central domain made up of four β-strands and this N-terminal domain. The N-terminal domain is essential for activity and provides the majority of the dimer interface. It is not yet clear whether this is its sole function or whether there is any additional regulatory role of this domain. It has no AdoMetDC activity and lacks the serine residue needed for processing that is described in the next section. Similar fusion proteins of AdoMetDC-like and aminopropyltransferase sequences are found in vertebrates, Deuterostomia, some Protostomia and some bacteria, but not in nematodes, plants, fungi and all sequenced single-cell eukaryotes with the exception of the ciliate Tetrahymena thermophila [9] . The fusion protein is present in sea anemone, Nematostella vectensis, which is the last common ancestor of cnidarians and bilaterians [9] .
Pyruvoyl prosthetic group and reaction mechanism All AdoMetDCs currently characterized belong to a small group of decarboxylating enzymes that use a covalently bound pyruvate as a prosthetic group rather than the cofactor PLP (pyridoxal 5 ′ -phosphate) typically employed in amino acid decarboxylation reactions [23] . Other examples of such pyruvoyl enzymes are phosphatidylserine decarboxylase, which forms phosphatidylethanolamine, aspartate-1-decarboxylase which forms β-alanine, and some, but not all, arginine and histidine decarboxylases.
The reactive carbonyl group of the pyruvate cofactor reacts with the substrate to form a Schiff base. This provides an electron sink via the amide carbonyl group of the pyruvate, and facilitates decarboxylation ( Figure 3A) . Protonation of the Cα of the product is then required to form the dcAdoMet, whose release regenerates the pyruvate. Structural and biochemical studies indicate that the side chain of residue Cys 82 in the human enzyme ( Figure 3B ) is responsible for this reaction [20, 24] . This amino acid is absolutely conserved in all AdoMetDCs ( Figure 2C) .
A disadvantage of the covalently bound pyruvate mechanism is that substrate-mediated transamination (see Figure 3A) , which can occur as a minor side reaction via protonation of the incorrect Cα of the cofactor, leads to the release of an aldehyde product and the formation of alanine in place of the pyruvate. This irreversibly inactivates the enzyme since the resulting alanine residue is covalently attached. Such substrate-mediated transamination can also occur with enzymes using PLP as the cofactor, but the pyridoxamine formed can be replaced by a new PLP molecule restoring activity. When Cys 82 is mutated to alanine in the human AdoMetDC, the reaction is greatly slowed and the rate of improper protonation and subsequent transamination is greatly increased [25] . This can be explained by another residue (probably His 243 ) that is not so well placed for correct protonation acting as the proton donor, either directly or via a water molecule. 
Formation of the pyruvate
The mechanism by which the pyruvate is generated was fi rst described by Snell and co-workers [26] more than 25 years ago on the basis of studies with histidine decarboxylase. The primary gene product is the single chain proenzyme (π chain). Formation of the active enzyme involves a self-maturation process of non-hydrolytic serinolysis in which the active-site pyruvoyl group is generated from an internal serine residue via an autocatalytic post-translational modifi cation. The two subunits (α and β) are formed in this reaction ( Figure 4A ). The initial event in this pathway involves the formation of an internal ester bond using the side-chain -OH group of the serine residue. After cleavage of this bond, the oxygen atom from the serine -OH group is used to form the C-terminus of the β chain, while the remainder of the serine residue is converted into ammonia and the pyruvoyl group at the N-terminus of the α chain ( Figure 4B ). Snell and co-workers [26] used 18 O-labelling to provide convincing evidence for this mechanism. No 18 O was incorporated into the C-terminus of the β chain when cleavage was carried out in H 2 18 O. When serine labelled with 18 O in the -OH group was used, the 18 O was transferred to the C-terminus of the β chain carboxylate.
The role of the protein in this autocatalytic mechanism is now understood in much more detail as a result of crystallographic studies of the protein structure and the results of site-directed mutagenesis of key residues. Much of this more recent work has been carried out with AdoMetDC. The human AdoMetDC π chain has 334 residues (38 kDa) and is converted into a 7.7 kDa (67 amino acids) β subunit and a 30.7 kDa α subunit, which contains 266 amino acids and the pyruvate group at its N-terminus ( Figure 4A ). The sequence VLSES 68 SMFV surrounding the residue that forms the pyruvate (Ser 68 ) is highly conserved in AdoMetDC proenzymes from the Class II enzymes ( Table 1) .
As expected from the mechanism shown in Figure 4 (B), replacement of the critical serine residue with any amino acid except cysteine or threonine completely prevents processing. Mutant AdoMetDCs with cysteine or threonine replacing this serine residue in the human or potato enzymes did process, albeit more slowly [14] . Replacement of the serine precursor with cysteine has no effect on the prosthetic group formed on cleavage, which is still pyruvate, but produces a thiocarboxylate group at the C-terminus of the β chain. This protein was still active [14] . Replacement of the serine with threonine generates an α-ketobutyrate prosthetic group. Although there is no reason that α-ketobutyrate cannot act in the same way as pyruvate and, indeed, the equivalent mutants in histidine decarboxylase or phosphatidylserine decarboxylase are active, the AdoMetDC mutant was not [14] .
The initial rearrangement step to form the ester linkage requires a proton acceptor ( Figure 4B ). This is likely to be the side chain of Ser 229 in human AdoMetDC. The structure of the π chain, which was determined using the non-processing S68A mutant, indicates that the -OH group is positioned appropriately to form a hydrogen bond [18] . Mutant S229A failed to process, and mutant S229C cleaved very slowly, whereas mutant S229T processed normally [25] . Mutation of residue His 243 prevented normal processing, which stopped after the ester formation step. This was demonstrated by the fi nding that the H243A mutant remained as a π chain, but this chain could be cleaved into a modifi ed α subunit with serine instead of pyruvate and the β subunit by mild treatment with hydroxylamine, which is known to break such ester bonds [25] . Determination of the crystal structure of the H243A mutant AdoMetDC protein has confi rmed directly that it contains an ester bond between residues 67 and 68 [19] . A basic residue is needed to extract the hydrogen of the α-carbon of Ser 68 in the ester to allow the β-elimination reaction that occurs to form the subunit with an N-terminal dehydroalanine residue ( Figure 4B ). His 243 is therefore likely to fulfi l this role and it is located in an appropriate position in the active site.
There is no signifi cant similarity in the amino acid sequence surrounding the serine-cleavage site between the Class I and Class II AdoMetDCs (Table  1) . However, conserved residues corresponding to His 243 and Ser 229 are positioned identically when the human and T. maritima sequences are compared ( Figure 2C ). Thus Ser 55′ is equivalent to Ser 229 and His 68′ is equivalent to His 243 [note that (′) means the residue comes from the other αβ unit in the dimer shown in Figures 2A and 2B ] [22] . Also, these residues can readily be identifi ed in the E. coli AdoMetDC amino acid sequence, where they are provided by Ser77′ and His111′ ( Figure 2C ). A major difference between the Class IA and Class IB AdoMetDCs is the presence of a 27 amino acid insertion immediately prior to the cleavage site in the Class IA enzymes. This sequence, which contains fi ve proline residues and a high concentration of negatively charged residues, would be expected to be very rigid and may play a role in the activation of the Class IA enzymes by Mg 2+ .
Comparison of the structures of the processed wild-type human AdoMetDC, the unprocessed S68A mutant and the ester-containing H243A mutant have indicated that there is actually very little overall structural change [18, 19] . Most of the changes occur at the Ser 68 site of pyruvoyl group formation and in nearby residues Leu 65 , Ser 66 , Glu 67 , Cys 82 , Ser 229 and His 243 . The remainder of the enzyme, including the two antiparallel β-strands that are joined by residues 65-68, shows very little alteration in structure. The activesite pocket, which obviously includes Ser 68 , must be compatible with the residues needed for catalysis and those needed for processing. This provides a serious constraint during the evolution of such pyruvoyl enzymes and may account for their relative rarity.
It is interesting that the fi rst stage in the processing of pyruvoyl enzymes is similar to that involved in protein splicing, a post-translational editing process that removes an intein from a precursor protein and ligates the surrounding exteins to form the mature protein [27] . This process also begins with the side chain -OH or -SH of the conserved intein N-terminal serine or cysteine attacking the carbonyl carbon atom of the preceding amino acid, resulting in an ester or thioester bond at the N-terminal splice site. However, instead of undergoing the cleavage reaction, this is then attacked by the -OH/-SH group of the serine/threonine/cysteine from the second extein resulting in N-terminal cleavage and formation of a branched intermediate. This intermediate is resolved by cleavage of the peptide bond at the C-terminal splice site due to cyclization of the intein C-terminal asparagine residue and a spontaneous O-N or S-N acyl rearrangement establishes a peptide bond between the exteins.
The active-site pocket and substrate binding Considerable insight into the catalytic reaction is provided by the crystal structures of human AdoMetDC with bound substrate analogues [20] . Both the α and β subunits contribute key residues to the active site. The AdoMet substrate is bound by interactions of the ribose -OH groups to Glu 247 and the adenine ring is stacked between the aromatic rings of residues Phe 7 and Phe 223 . Remarkably, the adenosyl moiety of the bound substrate is in the syn conformation. In solution, AdoMet would be expected to adopt the anti structure and most of the known structures of AdoMet bound to proteins show the anti conformation. Glu 247 is conserved in all AdoMetDCs; the two phenylalanine residues are sometimes replaced by other amino acids with aromatic ring side chains (see Figure 2C) .
The critical importance of Glu 247 , Phe 7 and Phe 223 has been confi rmed by site-directed mutagenesis. Mutation of either phenylalanine residue to alanine results in a large increase in the K m and a decrease in the k cat [20] . Mutation of residue Glu 247 to alanine increased the K m for AdoMetDC by >10-fold and alteration to aspartate had a smaller 6-fold increase, whereas conversion into glutamine, which would still allow interaction with the ribose, had no significant effect. Residues Cys 82 , Ser 229 and His 243 are positioned near the methionyl group of the substrate. As described above, Cys 82 is the essential proton donor and its mutation to alanine has a profound effect on the reaction. The roles of Ser 229 and His 243 are less readily addressed by site-directed mutagenesis, since these residues are needed for processing to form the pyruvate, but their proximity to the substrate in the active site suggests that they do play a role in the catalytic reaction. The Ser 229 mutations to threonine or cysteine, which do process, lead to a loss of >90% activity even from the processed protein [25] .
The Cys 82 residue in AdoMetDC, reacts readily with NO inactivating the enzyme. ODC is also inactivated by NO, which is therefore a potent inhibitor of polyamine synthesis [28] . Effects on polyamine synthesis may mediate some of the antiproliferative actions of NO.
Putrescine activation
The activation of AdoMetDC by putrescine links the supply of both substrates for spermidine synthase. Putrescine is therefore efficiently converted into spermidine. Mammalian cells and tissues contain much higher amounts of spermidine and spermine than putrescine, whereas in species that lack this putrescine activation, putrescine may be the predominant polyamine.
Mammalian AdoMetDC is activated by putrescine in two ways. The processing reaction is stimulated by putrescine [29] , and the catalytic activity of the enzyme is enhanced [30] [31] [32] . Recent structural and biochemical studies indicate that there is one putrescine-binding site per αβ unit located a significant distance from the active site between two central β-sheets of the enzyme and near the dimer interface (Figure 2A) . Putrescine binding to the (αβ) 2 dimer, which makes up the enzyme, is quite strongly co-operative [33] . The aliphatic chain of putrescine stacks against Phe 111 and Phe 285 . One end of putrescine is directly hydrogen-bonded to Asp 174 , Glu 15 and Thr 176 . The other end is hydrogen-bonded through water molecules to Glu 178 , Glu 15 , Glu 256 and Ser 113 . These results are consistent with results of site-directed mutagenesis in which residues Asp 174 , Glu 178 or Glu 256 were changed to the corresponding amides. Processing and activity of these mutants was not increased by putrescine [14, 34] .
The putrescine molecule is linked to the active site by several buried charged residues and its binding causes structural and electrostatic alterations at the active site. Binding of putrescine results in a reorganization of four aromatic residues (Phe 285 , Phe 315 , Tyr 318 and Phe 320 ) and a conformational change in a loop formed by residues 312-320. This shields putrescine from the external solvent, enhancing its electrostatic and hydrogen-bonding effects [33] .
The Class IIB AdoMetDC from potato is not activated by putrescine [14] . The overall structure of the potato protein is similar to that of the human, but the protein differs in two critical respects, which explains the lack of putrescine stimulation [15] . First, as described above, it is an αβ monomer. Secondly, several amino acid substitutions of residues in the buried region where the putrescinebinding site is located in the human protein provide basic side chains that mimic the role of putrescine in the human enzyme. Thus the electrostatic interactions affecting the active site are produced by these residues without need for a ligand.
Inhibition of AdoMetDC
There is much interest in the polyamine biosynthetic pathway as a target for drugs that can be used as anti-protozoal, cancer chemotherapeutic and cancer chemoprevention agents. Several potent inhibitors of AdoMetDC have been designed and tested [21, 35, 36] (Figure 5 ). The fi rst such inhibitor was MGBG [methylglyoxal bis(guanylhydrazone)], which was actually used as an anticancer drug in the 1960s before its ability to inhibit polyamine synthesis at the AdoMetDC step was discovered in 1972 [37] . Related diamidines, such as SAM486A (4-amidinoindan-1-one-2′-amidinohydrazone), which are more potent both as AdoMetDC inhibitors and as anticancer agents, were described in 1992 [37a] . The reason for the inhibition of AdoMetDC by these diamidines remained unclear until the crystal structures of AdoMetDC bound to the drugs were obtained [20] . These structures showed that the compounds are exactly the right length to span the entrance of the AdoMetDC active site via interactions of the two amidine groups at each end. One forms hydrogen bonds with Glu 247 (which normally interacts with the ribose -OH groups of AdoMet) and the other bonds with the side chain of Ser 229 and the main chain carbonyl group of Leu 65 . The spacer groups of the inhibitors are located between the two phenylalanine residues at positions 7 and 223, which normally provide stacking interactions with the adenine ring of the AdoMet substrate ( Figure 3B ). SAM486A is able to interact more strongly than MGBG in this way by virtue of its aromatic rings, thus accounting for its greater potency.
A number of nucleoside derivatives related to AdoMet containing reactive aminooxy-, hydrazino-or hydrazido-groups such as MHZPA {5′-deoxy-5′-[(3-hydrazinopropyl)methylamino]adenosine}, MAOEA {5′-deoxy-5′-[(2-aminooxyethyl)methylamino]adenosine} and AMA [S-(5′-deoxy-5′-adenosyl) methylthioethylhydroxylamine] have also been shown to be irreversible inhibitors ( [20, 21, 35] and references therein). They bind at the active site, forming a covalent linkage to the pyruvoyl prosthetic group and are potent inhibitors, but seem to be too reactive with other cellular compounds to be useful drugs. As with the substrate AdoMet, they adopt the syn conformation in the active site [20] . An 8-methyl substitution increases their effi ciency by favouring this conformation [21] . Other AdoMet analogues, including some with such 8-methyl substitutions that cannot be decarboxylated, but bind reversibly to the active site, have also been described including 8-methyl-MMTA (5′-deoxy-5′-dimethylsulfonio-8-methyladenosine) [21, 35] . These may be more useful as drugs despite being less potent.
The most promising irreversible inhibitor of AdoMetDC is probably Genz-644131 (5′-{[(Z)-4-amino-2-butenyl]methylamino}-5′-deoxy-8-methyla denosine), the recently described 8-methyl derivative of AbeAdo (see below) [36]. Genz-644131 has good potency, biostability and brain penetration and cured trypanosome infections in mice.
AbeAdo (5′-{[(Z)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine), also known as MDL73811, is a stable molecule that was designed 20 years ago as an enzyme-activated irreversible inhibitor of AdoMetDC [38] . The postulated mechanism of action of AbeAdo involves the formation of a Schiff base between the drug and the pyruvate, followed by an enzyme-mediated abstraction of a proton forming a conjugated imine, which could then react with a nucleophilic residue of AdoMetDC. AbeAdo is indeed a potent inactivator of AdoMetDC, but when recombinant human AdoMetDC was allowed to react with AbeAdo, the enzyme was inactivated by a transamination of the pyruvate group [39] , suggesting that its primary mechanism of action was actually to increase the incorrect protonation shown in Figure 3(A) . Irrespective of the mechanism of action, the increased potency of Genz-644131 over the parent compound is explained by the greater likelihood of the compound being in the syn confi guration.
Regulation of AdoMetDC content
In addition to the activation of AdoMetDC proenzyme processing and enzyme activity by putrescine described above, the amount of AdoMetDC protein is highly regulated to respond to the cellular need for polyamines. Therefore many physiological processes leading to increased growth raise the AdoMetDC content. Regulation can occur at multiple steps including transcription of the AdoMetDC gene, mRNA translation and protein turnover ( Figure 6 ) [31, 32] . The AdoMetDC amount is negatively regulated by increased polyamine content at all of these steps. Therefore drugs or pathophysiology that reduce polyamine levels increase the AdoMetDC content.
The mechanism by which transcription is increased is not well understood, although the gene contains a number of binding sites for key cell-regulatory transcription factors and may contain a polyamine-responsive element [32] . The best understood regulatory step in the synthesis of AdoMetDC is the translational regulation [40, 41] . This regulation is achieved by virtue of small ORFs (open reading frames) in the 5′-UTR (untranslated region) of the mRNA. Mammalian AdoMetDC mRNAs contain such an ORF, which is highly conserved and encodes the hexapeptide MAGDIS [40] . This ORF is located only 14 nucleotides from the 5′ end of the mRNA. Ribosomes binding to it stall just prior to termination. The stalling is actually related to the encoded MAGDIS sequence. Unless this is prevented, access to the downstream ORF that encodes the enzyme is blocked. Factors, such as polyamine levels affecting AdoMetDC synthesis, alter the effi ciency of this process and modulate the translation of the downstream AdoMetDC reading frame in this way [40] . Plant AdoMetDC mRNAs actually contain two conserved overlapping upstream ORFs in their 5′ leader sequence encoding peptides of two or three and approx. 50 amino acids respectively. The ORF encoding the smaller peptide, which is located 5′ to the larger ORF, is not inhibitory, but occludes the initiation codon of the second ORF. At high polyamine concentrations, this tiny ORF is ignored and binding of ribosomes to the second ORF translates it, giving sequence-dependent translational repression as for the MAGDIS sequence [41] . Upsteam ORFs that presumably have similar regulatory properties are found in the AdoMetDC mRNAs from many species [42] .
The mammalian AdoMetDC protein turns over rapidly via degradation by the 26S proteasome after polyubiquitination [32, 43] . This turnover is more rapid when polyamine levels are high. It is possible that the degradation of the inactive transaminated form of the enzyme produced by incorrect catalytic turnover, as described in Figure 3(A) , is related to this. Increased fl ux through the AdoMetDC enzyme, which is needed for a high rate of polyamine synthesis, would increase the extent of such substrate-mediated transamination. Evidence that the polyubiquitination of the AdoMetDC protein and proteasomal degradation are enhanced after transamination has been published [44] . The reversible inhibitors described above that block the active site, such as MGBG and SAM486A, greatly stabilize AdoMetDC and thus have the unwanted effect of increasing its concentration, whereas treatment with AbeAdo causes a loss of the protein [32, 44] . These observations are compatible with the model in which transamination precedes degradation. The site of ubiquitination is currently unknown, but it may be speculated that the formation of alanine at the N-terminus of the α subunit generates such a site or causes a structural alteration allowing the recognition by ubiquitin ligases.
Conclusions
AdoMetDC is a potentially important target for drug design. The proenzyme processing leading to the formation of its pyruvate prosthetic group and its catalytic mechanism are relatively well understood. Some further work on the structures of the Class IA and IIC AdoMetDC enzymes for which only models are currently available would be helpful, but current knowledge based on the Class IIA, IIB and IB enzymes combined with the database provided by the inhibitors currently available should allow for the design and synthesis of more potent and species specifi c inactivators. It is surprising that little attention has yet been given to the opportunities for drug design provided by the processing reaction; blocking this process or preferably causing an abortive cleavage without pyruvate formation is an attractive and novel route to interfering with AdoMetDC activity. The intricate regulation of AdoMetDC content and activity and its importance are an ongoing research area that is vitally important to a complete understanding of the control of polyamine levels. Clearly, more needs to be determined on the transcriptional regulation and on the mechanism for the rapid turnover of the AdoMetDC protein. The potential interaction of AdoMetDC with spermine synthase, and the extent to which the proenzyme (π′) subunit discovered in trypanosomes regulates activity in other species are exciting new areas for further study. 
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